Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Importance: Limited evidence exists to support cognitive intervention improving the daily function of adults with subjective cognitive decline (SCD).
Objective: To examine the preliminary efficacy of a group-based multicomponent cognitive intervention that integrates Lifestyle Redesign® (LR) techniques.
Design: Single-arm two-period crossover trial; 16-wk waiting period, 16-wk intervention, and 16-wk follow-up.
Setting: Memory clinic in a medical center, Taiwan.
Participants: Purposive sample of adults ages >55 yr with SCD.
Intervention: Sixteen 1.5-hr weekly multicomponent sessions of cognitive training, cognitive rehabilitation, psychological intervention, and lifestyle intervention.
Outcomes And Measures: Primary outcomes were (1) self-reported daily function, measured with the Activities of Daily Living Questionnaire (ADLQ) and Cognitive Failure Questionnaire; (2) performance-based daily function, measured with the Brief University of California San Diego Performance-Based Skills Assessment-Traditional Chinese Version; and (3) functional cognition, measured with the Contextual Memory Test (CMT) and Miami Prospective Memory Test. Secondary outcomes included cognitive functions, anxiety, and depression.
Results: Seventeen participants completed the intervention; 4 missed the follow-up. The generalized estimating equations model showed significant changes from baseline to pretest (control) and pretest to posttest (intervention) on the ADLQ (p = .014) and CMT-delayed (p = .003). Effects remained at the 16-wk follow-up. After adjusting for the effects of covariates, the self-reported daily function of participants ages ≤ 63 yr improved more than that of other participants (p = .003).
Conclusions And Relevance: Multicomponent cognitive interventions integrating LR techniques may improve self-reported daily function and context-dependent memory function of adults with SCD, with efficacy sustained at follow-up. What This Article Adds: A group-based multicomponent cognitive intervention consisting of cognitive training, cognitive rehabilitation, psychoeducation, and lifestyle intervention may provide benefits for the daily function and cognitive function of adults with SCD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5014/ajot.2023.050133 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term recovery of sensorimotor functions and prediction of participation in survivors of critical illness: a prospective cohort study.
J Intensive Care
September 2025
German Center for Vertigo and Balance Disorders, Ludwig-Maximilians-Universitat (LMU), University Hospital Grosshadern, Munich, Germany.
Background: Survivors of critical illness frequently face physical, cognitive and psychological impairments after intensive care. Sensorimotor impairments potentially have a negative impact on participation. However, comprehensive understanding of sensorimotor recovery and participation in survivors of critical illness is limited.
View Article and Find Full Text PDFPatient-centred interprofessional teleconsultation for post-viral symptom complexes in German primary care-protocol for the cluster-randomised controlled COVI-Care M-V trial.
BMC Health Serv Res
September 2025
Institute of General Practice, Rostock University Medical Center, Doberaner Str. 142, Rostock, 18057, Germany.
Background: Post-viral syndromes, including long- and post-COVID, often lead to persistent symptoms such as fatigue and dyspnoea, affecting patients' daily lives and ability to work. The COVI-Care M-V trial examines whether interprofessional, patient-centred teleconsultations, initiated by general practitioners in cooperation with specialists, can help reduce symptom burden and improve care for patients.
Methods: To evaluate the effectiveness of the intervention under routine care conditions, a cluster-randomised controlled trial is being conducted.
Patient-reported outcomes after lobectomy vs. segmentectomy for early-stage non-small cell lung cancer.
Surg Endosc
September 2025
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Background: Surgical resection is the cornerstone for early-stage non-small cell lung cancer (NSCLC), with lobectomy historically standard. Evolving techniques have spurred debate comparing lobectomy and segmentectomy. This study analyzed early postoperative patient-reported symptoms and functional status in patients with early NSCLC undergoing either procedure.
View Article and Find Full Text PDFA pilot study examining a ketogenic diet as an adjunct therapy in college students with major depressive disorder.
Transl Psychiatry
September 2025
Department of Human Sciences, The Ohio State University, Columbus, OH, USA.
A ketogenic diet (KD) has shown promise as an adjunctive therapy for neurological and neuropsychiatric disorders, including bipolar disorder and major depressive disorder (MDD). We examined tolerance for a KD in young adults with MDD and assessed symptoms of depression and metabolic health. Students (n = 24) with a confirmed diagnosis of MDD at baseline receiving standard of care counseling and/or medication treatment were enrolled in a 10-12 week KD intervention that included partial provision of ketogenic-appropriate food items, frequent dietary counseling, and daily morning tracking of capillary R-beta-hydroxybutyrate (R-BHB).
View Article and Find Full Text PDFDiscovery of a selective alpha-kinase 1 inhibitor for the rare genetic disease ROSAH syndrome.
Nat Commun
September 2025
Shanghai Yao Yuan Biotechnology Ltd (Drug Farm), Shanghai, China.
ROSAH (retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and headache) syndrome is a rare genetic disease caused by variants in alpha-kinase 1 (ALPK1) resulting in downstream pro-inflammatory signaling mediated by the TIFA/TRAF6/NF-κB pathway. Here, we report the design of an ALPK1 inhibitor, DF-003, with pharmacokinetic properties suitable for daily oral dosing. In biochemical assays, DF-003 potently inhibits human ALPK1 (IC = 1.
View Article and Find Full Text PDF